Company intelligence / Profile preview

Beijing Diwei Huayu Biotechnology

Ownership: Private
Development stage: Other

Overview

Beijing Diwei Huayu Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to the development of innovative vaccines and therapeutic biologics. The company utilizes a proprietary mRNA technology platform and recombinant protein expression systems to target high-burden infectious diseases. Its lead programs include an mRNA-based COVID-19 vaccine candidate and a recombinant rabies vaccine. Diwei Huayu aims to provide effective and accessible immunization solutions through its integrated R&D and manufacturing capabilities. The company operates out of the Zhongguancun Science Park's Daxing Bio-medicine Industry Base.

Therapeutic areas: Infectious Diseases
Modalities: mRNA-based drugsVaccineRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Beijing Diwei Huayu Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Diwei Huayu Biotechnology.